Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363512 | 0.85 | DPP4 (0.64) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL14187258 | 0.84 | DPP4 (0.77) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2667448 | 0.79 | DPP4 (0.75) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL14187434 | 0.78 | DPP4 (0.73) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8362642 | 0.78 | DPP4 (0.62) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL2667530 | 0.78 | DPP4 (0.77) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8364721 | 0.76 | DPP4 (0.76) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL13593626 | 0.76 | DPP4 (0.76) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8362641 | 0.74 | DPP4 (0.60) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL22178608 | 0.74 | DPP4 (0.74) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7906503-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728141-B2 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1682550-B1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. | 2007-02-08 | — | — | US | disclosed |
| WO-2003004498-A1 | BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885DPP8 35/4885DPP7 16/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | DPP4 158/4885DPP8 378/4885DPP7 263/4885 |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | CNR1, CNR2, FAAH | DPP4 1050/4885DPP8 2315/4885DPP7 2326/4885 |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | CNR2, CNR1, CHRNA4 | DPP4 1734/4885DPP8 3701/4885DPP7 2445/4885 |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | CNR1, CNR2, MAG | DPP4 2758/4885DPP8 2453/4885DPP7 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.